Connect with us

Hi, what are you looking for?

Home » World » WHO Approves Two New Treatments For COVID-19 Patients


WHO Approves Two New Treatments For COVID-19 Patients

The experts from the global health watchdog made a recommendation in British medical Journal- the BMJ.

In the image Doctor-checks on Covid019 patient. Photo used for representational purposes. (Source: PTI Image)

New Delhi: The World Health Organisation (WHO) on Friday made two new treatment recommendations including an arthritis drug to treat Coronavirus disease among patients.

The two treatments include one for serious and critical COVID-19 patients while another recommendation was for non-serious infections.

The experts from the global health watchdog made a recommendation in British medical Journal- the BMJ, for Baricitinib and Sotrovimab.

Baricitinib, which is also used to treat rheumatoid arthritis, is strongly recommended for patients with severe or critical covid-19 in combination with corticosteroids. The experts added that there is “evidence that Baricitinib improved survival and reduced the need for ventilation, with no observed increase in adverse effects.”

ALSO READ: Doctors, Health Workers Test Covid-19 Positive As Infections Surge In Telangana

“Baricitinib has similar effects to interleukin 6 inhibitors, which are also used to treat arthritis, so when both drugs are available the expert group suggests choosing one on the basis of cost, availability, and clinician experience,” the recommendation made in the journal read. However, it added that it does not recommend using both drugs at the same time.

The WHO group also made a conditional recommendation for the use of the monoclonal antibody Sotrovimab for non-severe COVID-19 patients, who also have highest risk of hospital admission, reflecting fewer benefits in those at lower risk.

According to the British journal, last December the UK’s Medicines and Healthcare Products Regulatory Agency approved Sotrovimab for people aged over 12 with mild to moderate covid-19 who were at high risk of developing severe disease, after it was shown to reduce the risk of hospital admission and death by 79 per cent in high-risk adults with symptomatic COVID-19.

Further, the WHO expert panel recommended against the use of two other drugs—Ruxolitinib and Tofacitinib—in patients with severe or critical COVID-19. The WHO expert explained that evidence from small trials failed to show benefit and suggested a possible increase in serious side effects with Tofacitinib.

ALSO READ: Covaxin Now Universal Covid Vaccine For Adults And Kids: Bharat Biotech

Advertisement. Scroll to continue reading.
Read Full Article



In at least four seats in Goa, including the prestigious Panaji constituency, BJP has witnessed dissent from former party members.


According to the designer, the blue pantsuit with black polka dots will make Minnie Mouse "A symbol of progress".


EVERY year as February nears, there’s much chatter about the Union Budget on every platform. If you’re a millennial, there’s a high chance that...


Two years on, eight countries have managed to stay away from the pandemic, reporting zero cases, and have remained largely untouched by the virus.


The pothole-ridden roads have become a nightmare for its residents in Bengaluru.

You May Also Like


Several students' organisations, including the All India Students Association (AISA), called for the state-wide bandh on Friday to protest against the alleged irregularities in...


The cause of death will be determined after the postmortem results.


Jats are a deciding factor in almost all the seats in western Uttar Pradesh, a region where the RLD enjoys influence among the community.


BrahMos missile deal is also India’s first major weapon sale.